Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 101: Which of the following are β-blockers with intrinsic sympathomimetic properties?

A. Propranolol
B. Oxprenolol
C. Pindolol
D. Esmolol (Correct Answer)

Explanation: **Explanation:** The question asks for $\beta$-blockers with **Intrinsic Sympathomimetic Activity (ISA)**. ISA refers to the ability of certain $\beta$-blockers to act as **partial agonists**; they block the receptor at high catecholamine levels but cause low-level stimulation when catecholamine levels are low. This property results in less resting bradycardia and less withdrawal syndrome compared to pure antagonists. **Analysis of Options:** * **Pindolol and Oxprenolol (Options B & C):** These are the classic examples of $\beta$-blockers with significant ISA. They are often preferred in patients who require $\beta$-blockade but have a tendency toward symptomatic bradycardia. * **Propranolol (Option A):** This is a prototype non-selective $\beta$-blocker with **no ISA**. It possesses membrane-stabilizing activity (MSA) but acts as a pure antagonist. * **Esmolol (Option D):** This is an ultra-short-acting, cardioselective ($\beta_1$) blocker with **no ISA**. It is metabolized by RBC esterases and is used intravenously for hypertensive emergencies or supraventricular tachycardias. ***Note on the Question Key:*** *There appears to be a discrepancy in the provided key. In standard pharmacological classification, **Pindolol and Oxprenolol** possess ISA, while **Esmolol** does not. For NEET-PG, always remember the mnemonic "Patients Are Not Pure" (Pindolol, Acebutolol, Nilevolol, Penbutolol) for drugs with ISA.* **High-Yield Clinical Pearls for NEET-PG:** * **ISA Advantage:** Useful in patients with bradycardia or peripheral vascular disease (less cold extremities). * **Esmolol:** Shortest half-life (~9 minutes); used in aortic dissection and perioperative tachycardia. * **Propranolol:** Highly lipid-soluble; used for prophylaxis of migraine, essential tremors, and portal hypertension. * **Sotalol:** A $\beta$-blocker that also exhibits Class III antiarrhythmic properties (K+ channel blockade).

Question 102: Levosimendan is approved in which of the following conditions?

A. Heart failure (Correct Answer)
B. Kidney failure
C. Liver failure
D. Endocrine crisis

Explanation: **Explanation:** **Levosimendan** is a novel cardiovascular drug classified as a **Calcium Sensitizer**. It is primarily used in the management of **acutely decompensated heart failure (ADHF)** where conventional therapies are insufficient. **Why Option A is Correct:** Levosimendan exerts its effect through a dual mechanism of action: 1. **Inotropic Effect:** It binds to cardiac **Troponin C** in a calcium-dependent manner. This increases the sensitivity of myofilaments to existing calcium, enhancing myocardial contractility without increasing intracellular calcium levels. Crucially, this improves stroke volume without significantly increasing myocardial oxygen demand or causing arrhythmias. 2. **Vasodilation:** It opens **ATP-sensitive potassium (K+ATP) channels** in vascular smooth muscle, leading to peripheral and coronary vasodilation (Inodilator). This reduces both preload and afterload. **Why Other Options are Incorrect:** * **B & C (Kidney/Liver Failure):** Levosimendan is not a treatment for organ failure in these systems. In fact, its active metabolite (OR-1896) is excreted renally, requiring cautious use or dose adjustment in severe renal impairment. * **D (Endocrine Crisis):** Conditions like thyroid storm or Addisonian crisis require specific hormonal stabilization (e.g., beta-blockers, steroids), not calcium sensitizers. **High-Yield Clinical Pearls for NEET-PG:** * **Unique Feature:** Unlike Dobutamine or Milrinone, Levosimendan does not increase intracellular calcium, making it less likely to cause calcium-overload-induced arrhythmias. * **Inodilator:** It belongs to the "Inodilator" class (Inotrope + Vasodilator). * **Indication:** Short-term treatment of severe ADHF when standard inotropes are inadequate. * **Side Effects:** Hypotension (due to vasodilation) and headache are the most common adverse effects.

Question 103: All of the following electrocardiographic findings may represent manifestations of digitalis intoxication, except?

A. Bigeminy
B. Junctional tachycardia
C. Atrial flutter (Correct Answer)
D. Atrial tachycardia with variable block

Explanation: **Explanation** Digitalis (Digoxin) has a complex effect on cardiac tissue, increasing vagal tone while simultaneously increasing myocardial excitability (automaticity). In toxic doses, it can cause almost any type of arrhythmia, but **Atrial Flutter** and **Atrial Fibrillation** are exceptionally rare manifestations of toxicity. **Why Atrial Flutter is the Correct Answer:** Digitalis toxicity typically increases the refractory period of the AV node and decreases the refractory period of the atria. However, it rarely triggers the specific macro-reentrant circuit required for atrial flutter. In fact, Digoxin is often used to *treat* atrial flutter by slowing the ventricular rate. **Analysis of Other Options:** * **Bigeminy (Option A):** Ventricular bigeminy is the most common and characteristic rhythm associated with digitalis toxicity. It occurs due to increased automaticity and delayed after-depolarizations (DADs). * **Junctional Tachycardia (Option B):** Digoxin enhances the automaticity of the AV junction. Non-paroxysmal junctional tachycardia is a highly specific sign of digitalis toxicity. * **Atrial Tachycardia with Variable Block (Option C):** This is considered the most "classic" or pathognomonic arrhythmia of digitalis toxicity. It results from a combination of increased atrial excitability (causing tachycardia) and increased vagal effect on the AV node (causing the block). **High-Yield Clinical Pearls for NEET-PG:** * **Earliest Sign of Toxicity:** Gastrointestinal symptoms (Anorexia, nausea, vomiting). * **Most Common Arrhythmia:** Ventricular Bigeminy. * **Most Specific Arrhythmia:** Atrial tachycardia with AV block. * **Visual Disturbance:** Xanthopsia (yellow-green vision). * **Electrolyte Interaction:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digitalis toxicity. * **Antidote:** Digoxin-specific antibody fragments (DigiFab).

Question 104: Which of the following is used to treat severe pulmonary hypertension?

A. Angiotensin I
B. Omapatrilat
C. Bosentan (Correct Answer)
D. Endothelin

Explanation: **Explanation:** **Bosentan** is the correct answer because it is a **non-selective endothelin receptor antagonist (ERA)**. It blocks both $ET_A$ and $ET_B$ receptors, which are responsible for the potent vasoconstrictive and proliferative effects of Endothelin-1. By inhibiting these receptors, Bosentan reduces pulmonary vascular resistance, making it a first-line oral therapy for **WHO Group 1 Pulmonary Arterial Hypertension (PAH)**. **Analysis of Incorrect Options:** * **Angiotensin I (A):** This is a precursor to Angiotensin II. It has no direct therapeutic role in pulmonary hypertension; in fact, its conversion to Angiotensin II would lead to systemic vasoconstriction. * **Omapatrilat (B):** This is a **Vasopeptidase inhibitor** that inhibits both Neprilysin and ACE. While it was studied for systemic hypertension and heart failure, it is not used for pulmonary hypertension and was never FDA-approved due to a high risk of angioedema. * **Endothelin (D):** This is a potent endogenous **vasoconstrictor**. Administering endothelin would severely worsen pulmonary hypertension by causing further narrowing of the pulmonary arteries. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Bosentan is a competitive antagonist at $ET_A$ and $ET_B$ receptors. * **Side Effects:** The most significant side effect is **Hepatotoxicity** (requires monthly LFT monitoring). It is also highly **Teratogenic** (Category X), necessitating a negative pregnancy test before starting therapy. * **Other ERAs:** **Ambrisentan** (selective $ET_A$ blocker) and **Macitentan** (tissue-selective non-selective blocker). * **Other PAH Treatments:** Sildenafil (PDE-5 inhibitor), Epoprostenol (Prostacyclin analogue), and Riociguat (Guanylate cyclase stimulator).

Question 105: A hypertensive patient on beta-blocker medication develops severe bradycardia. Which of the following is least likely to be the responsible agent?

A. Metoprolol
B. Nadolol
C. Pindolol (Correct Answer)
D. Atenolol

Explanation: **Explanation:** The core concept in this question is **Intrinsic Sympathomimetic Activity (ISA)**, also known as partial agonist activity. **Why Pindolol is the correct answer:** Pindolol is a non-selective beta-blocker that possesses significant **Intrinsic Sympathomimetic Activity (ISA)**. Unlike pure beta-blockers, pindolol partially stimulates beta-receptors while simultaneously blocking them from stronger catecholamine stimulation. Because it provides a low level of "background" stimulation, it causes significantly less bradycardia at rest compared to other beta-blockers. In some cases, it may even slightly increase the resting heart rate, making it the least likely agent among the choices to cause severe bradycardia. **Why the other options are incorrect:** * **Metoprolol (A) and Atenolol (D):** These are cardioselective ($\beta_1$) blockers. They lack ISA and are well-known for causing a dose-dependent decrease in heart rate (bradycardia) by blocking $\beta_1$ receptors in the SA and AV nodes. * **Nadolol (B):** This is a long-acting, non-selective beta-blocker without ISA. It is highly potent and frequently associated with significant bradycardia. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-blockers with ISA:** Pindolol, Acebutolol, Alprenolol, and Oxprenolol. (Mnemonic: **P**a**A****A****O** - **P**indolol, **A**cebutolol, **A**lprenolol, **O**xprenolol). * **Clinical Use:** Drugs with ISA are preferred in hypertensive patients who have pre-existing bradycardia or a low cardiac reserve. * **Contraindication:** Beta-blockers with ISA are generally avoided in patients with angina or post-myocardial infarction because they do not reduce the resting heart rate or myocardial oxygen demand as effectively as pure antagonists.

Question 106: Adverse effects of losartan are all except?

A. Fetopathic
B. Cough (Correct Answer)
C. Hyperkalemia
D. Headache

Explanation: **Explanation:** The correct answer is **Cough (Option B)**. **1. Why Cough is the correct answer:** Losartan belongs to the class of **Angiotensin II Receptor Blockers (ARBs)**. Unlike ACE inhibitors (e.g., Enalapril), ARBs do not inhibit the enzyme Kininase II. Therefore, they do not lead to the accumulation of **bradykinin and substance P** in the lungs. Since the accumulation of these inflammatory mediators is the primary cause of the characteristic "dry cough" associated with ACE inhibitors, ARBs like Losartan are notably free from this side effect. **2. Analysis of Incorrect Options:** * **Fetopathic (Option A):** Like ACE inhibitors, ARBs are **teratogenic**. They can cause fetal renal dysgenesis, oligohydramnios, and skull hypoplasia. They are strictly contraindicated in pregnancy (Category D). * **Hyperkalemia (Option C):** By blocking the effects of Angiotensin II, ARBs reduce **aldosterone secretion**. This leads to potassium retention in the distal tubules, potentially causing hyperkalemia, especially in patients with renal impairment or those taking potassium-sparing diuretics. * **Headache (Option D):** This is one of the most commonly reported non-specific side effects of Losartan, along with dizziness and fatigue. **3. NEET-PG High-Yield Pearls:** * **Losartan’s Unique Property:** It is the only ARB that has a **uricosuric effect** (increases uric acid excretion), making it a preferred antihypertensive in patients with **Gout**. * **First-Dose Hypotension:** While more common with ACE inhibitors, it can occur with ARBs, particularly in volume-depleted patients. * **Clinical Switch:** If a patient develops a dry cough on an ACE inhibitor, the most appropriate next step is to switch them to an **ARB**.

Question 107: What is the drug of choice for cardiogenic shock?

A. Dopamine (Correct Answer)
B. Propranolol
C. Digitalis
D. Milrinone

Explanation: **Explanation:** **Dopamine** is traditionally considered the drug of choice for cardiogenic shock because of its unique dose-dependent receptor activity. In the management of shock, it provides a balanced approach: at medium doses (2–10 µg/kg/min), it stimulates **β1-receptors**, increasing myocardial contractility (inotropy) and heart rate (chronotropy). At higher doses (>10 µg/kg/min), it stimulates **α1-receptors**, causing vasoconstriction to maintain systemic blood pressure. This dual action helps improve cardiac output while ensuring adequate perfusion pressure. **Analysis of Incorrect Options:** * **Propranolol:** This is a non-selective β-blocker. It decreases heart rate and contractility, which would worsen heart failure and potentially be fatal in cardiogenic shock. * **Digitalis:** While it increases inotropy, its onset of action is too slow for acute shock management, and it does not provide the necessary vasopressor support. * **Milrinone:** A PDE-3 inhibitor that increases inotropy but also causes significant systemic vasodilation (inodilator). This can lead to a dangerous drop in blood pressure if the patient is already hypotensive. **High-Yield Clinical Pearls for NEET-PG:** * **Dobutamine vs. Dopamine:** Dobutamine is often preferred if the systolic BP is >90 mmHg because it is a more potent inotrope with less effect on heart rate. However, if the patient is severely hypotensive (SBP <70-80 mmHg), Dopamine or Norepinephrine is preferred. * **Renal Dose Myth:** The "low-dose" dopamine (0.5–2 µg/kg/min) for renal protection is no longer clinically recommended as it does not improve outcomes in acute renal failure. * **Norepinephrine:** Recent guidelines often favor Norepinephrine over Dopamine in cardiogenic shock due to a lower risk of arrhythmias. However, per standard textbooks and traditional MCQ patterns, Dopamine remains the classic answer.

Question 108: Which of the following is the best drug for treating hypertension in a diabetic patient?

A. Losartan (Correct Answer)
B. Propranolol
C. Thiazides
D. All of the above

Explanation: ### Explanation **Correct Answer: A. Losartan** **1. Why Losartan is the Correct Choice:** In diabetic patients, the primary goal of antihypertensive therapy is not just blood pressure control, but also **renoprotection**. Losartan is an Angiotensin II Receptor Blocker (ARB). Both ACE inhibitors (like Enalapril) and ARBs (like Losartan) are considered first-line agents for diabetics because they: * **Dilate the efferent arteriole** more than the afferent arteriole, reducing intraglomerular pressure. * Decrease **proteinuria** and slow the progression of diabetic nephropathy. * Are metabolically neutral (do not affect glucose levels). **2. Why Other Options are Incorrect:** * **B. Propranolol:** This is a non-selective beta-blocker. It is generally avoided in diabetics because it can **mask the warning symptoms of hypoglycemia** (like tachycardia and tremors) and may impair glycogenolysis, leading to prolonged hypoglycemic episodes. * **C. Thiazides:** While effective antihypertensives, high doses of Thiazides can cause **hyperglycemia** (by inhibiting insulin release and reducing peripheral glucose utilization) and hyperlipidemia, which can worsen the metabolic profile of a diabetic patient. * **D. All of the above:** Incorrect, as options B and C have significant metabolic disadvantages for diabetics. **3. NEET-PG Clinical Pearls:** * **Drug of Choice:** ACE inhibitors are usually the first choice; ARBs (Losartan) are the best alternative if the patient develops an ACEI-induced dry cough. * **Renal Artery Stenosis:** Both ACEIs and ARBs are strictly **contraindicated** in bilateral renal artery stenosis as they can precipitate acute renal failure. * **Pregnancy:** These drugs are **teratogenic** (cause fetal renal dysgenesis) and must be avoided. * **Electrolyte Imbalance:** Always monitor for **hyperkalemia** when a patient is on Losartan.

Question 109: Digoxin toxicity is enhanced by all, except?

A. Quinidine
B. Hypokalemia
C. Hypomagnesemia
D. Hepatic dysfunction (Correct Answer)

Explanation: **Explanation:** The correct answer is **Hepatic dysfunction** because Digoxin is primarily excreted unchanged by the **kidneys (approx. 60-80%)**. Unlike many other drugs, it does not undergo significant hepatic metabolism. Therefore, liver failure does not significantly affect its serum levels or toxicity profile. In contrast, **renal failure** is a major risk factor for digoxin toxicity. **Analysis of other options:** * **Quinidine (Option A):** Increases digoxin levels by displacing it from tissue binding sites and reducing its renal clearance (via inhibition of P-glycoprotein). This is a classic drug interaction. * **Hypokalemia (Option B):** Digoxin competes with Potassium ($K^+$) for binding at the $Na^+/K^+$-ATPase pump. Low extracellular potassium allows more digoxin to bind to the pump, significantly enhancing its toxic effects. * **Hypomagnesemia (Option C):** Low magnesium sensitizes the myocardium to digoxin-induced arrhythmias, as magnesium is a necessary cofactor for the $Na^+/K^+$-ATPase pump. **High-Yield Clinical Pearls for NEET-PG:** 1. **Electrolyte Triad of Toxicity:** Digoxin toxicity is worsened by **Hypokalemia, Hypomagnesemia, and Hypercalcemia** ("Hypo-Hypo-Hyper"). 2. **Drug Interactions:** Apart from Quinidine, drugs like **Verapamil, Amiodarone, and Spironolactone** also increase digoxin levels. 3. **Antidote:** The specific antidote for life-threatening toxicity is **Digoxin Immune Fab (Digibind)**. 4. **ECG Sign:** The earliest sign of toxicity is often PVCs; the most characteristic sign is **Paroxysmal Atrial Tachycardia with AV block**. The "reverse tick" or "sagging" ST segment indicates digoxin *effect*, not necessarily toxicity.

Question 110: The progression of which of the following conditions is retarded by chronic use of enalapril?

A. Diabetic nephropathy
B. Diabetic retinopathy
C. Hypertensive nephropathy
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. All of the above**. Enalapril is an ACE inhibitor (ACEi) that provides significant organ protection beyond its blood pressure-lowering effects. **1. Diabetic Nephropathy:** ACE inhibitors are the drugs of choice for preventing the progression of diabetic kidney disease. They cause **efferent arteriolar vasodilation**, which reduces intraglomerular pressure. This decreases mechanical stress on the basement membrane and reduces proteinuria (microalbuminuria), thereby retarding the progression to end-stage renal disease (ESRD). **2. Diabetic Retinal Disease:** Chronic ACE inhibition has been shown to reduce the risk of progression of retinopathy in diabetic patients (as seen in the EUCLID study). By inhibiting the local Renin-Angiotensin System (RAS) in the eye, ACE inhibitors reduce vascular endothelial growth factor (VEGF) expression and inflammatory markers, slowing retinal damage. **3. Hypertensive Nephropathy:** Similar to diabetic nephropathy, ACE inhibitors protect the kidneys from hypertensive damage by reducing systemic blood pressure and intra-renal barotrauma. **Clinical Pearls for NEET-PG:** * **Renoprotection:** ACE inhibitors/ARBs are the first-line antihypertensives in patients with diabetes or chronic kidney disease (CKD) with proteinuria. * **Contraindication:** They are strictly contraindicated in **Bilateral Renal Artery Stenosis** (can cause acute renal failure) and **Pregnancy** (teratogenic; causes fetal renal dysgenesis). * **Side Effects:** Remember the mnemonic **CAPTOPRIL**: **C**ough (due to Bradykinin), **A**ngioedema, **P**otassium excess (Hyperkalemia), **T**aste changes, **O**rthostatic hypotension, **P**regnancy contraindication, **R**enal artery stenosis contraindication, **I**ncreased renin, **L**eukopenia.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free